Preeclampsia in pregnancy-prediction, prevention and further management;Preeklampsie v těhotenství-predikce, prevence a další management

Ceska Gynekologie

Volumn 79, Issue 5, 2014, Pages 356-362

  Leahomschi, S ^a   Calda, P ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Aspirin; PlGF; Prediction; Preeclampsia; Prevention; Screening; SFlt 1

Indexed keywords

EID: 84923604828     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Ahmad, S., et al. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res, 2004, 95, p. 884-891.
2. Akolekar, R., Syngelaki, A., Poon, L., et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther, 2013, 33(1), p. 8-15.
3. Alahakoon, TI., et al. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro-and anti-angiogenic profiles. J Matern Fetal Neonatal Med, 2014, Feb 3. [Epub ahead of print]
4. Alanis, MC., Robinson, CJ., Hulsey, TC., et al. Early-onset severe preeclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am J Obstet Gynecol, 2008, 199, p. 262.e1-262.e6.
5. Al-Jameil, N., et al. A brief overview of preeclampsia. J Clin Med Res, 2014, 6(1), p. 1-7.
6. Audibert, F., Boucoiran, I., An, N., et al. Screening for preeclampsia using firsttrimester serum markers and uterine artery Doppler in nulliparous women. Am J Obstet Gynecol, 2010, 203, 383, p. e1-8.
7. Brennan, LJ., et al. Vascular dysfunction in preeclampsia. Microcirculation, 2014, 21(1), p. 4-14.
8. Bujold, E., Roberge, S., Lacasse, Y., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol, 2010, 116, p. 402-414.
9. Caritis, S., et al. Low-dose aspirin to prevent preeclampsia in women at high risk. N Engl J Med, 1998, 338(11), p. 701-705.
10. Cnossen, JS., Morris, RK., ter Riet, G., et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ, 2008, 1768, p. 701-711.
11. Di Sessa, TG., et al. Cardiac function in fetuses and newborns exposed to low-dose aspirin during prengancy. Am J Obstet Gynecol, 1994, 171(4), p. 892-900.
12. Duley, L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 2009, 33(3), p. 130-137.
13. Duley, L., et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007 Apr 18, (2):CD004659.
14. Erez, O., et al. Preeclampsia in twin gestations: association with IVF treatments, parity and maternal age. J Matern Fetal Neonatal Med, 2006, 19(3), p. 141-146.
15. Escudero, C., et al. Impaired adenosine-mediated angiogenesis in preeclampsia: potential implications for fetal programming. Front Pharmacol, 2014, 5, p. 134.
16. Espinoza, J. Recent biomarkers for the identification of patients at risk for preeclampsia: the role of uteroplacental ischemia. Expert Opin Med Diagn, 2012, 6(2), p. 121-130.
17. Geographic variation in the incidence of hypertension in pregnancy. World Health Organization International Collaborative Study of Hypertensive Disorders of Pregnancy. Am J Obstet Gynecol, 1988, 158(1), p. 80-83.
18. Gilbert, J., et al. Recombinant VEGF-121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension, 2010, 55(2), p. 380-385.
19. Hernandez-Diaz, S., et al. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ, 2009, 338, p. 2255.
20. Hutcheon, JA., et al. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol, 2011, 25(4), p. 391-403.
21. Jacquemyn, Y., Zemtsova, O. Risk factors and prediction of preeclampsia. Acta Clin Belg, 2010, 65(1), p. 1-12.
22. Jeyabalan, A. Epidemiology of preeclampsia: impact of obesity. Nutr Rev, 2013, 71, Suppl 1, p. S18-25.
23. Khan, KS., et al. WHO analysis of causes of maternal death: a systematic review. Lancet, 2006, 367(9516), p. 1066-1074.
24. Klebanoff, MA., Berendes, HW. Aspirin exposure during the first 20 weeks of gestation and IQ at four years of age. Teratology, 1988, 37(3), p. 249-255.
25. Kuc, S., Wortelboer, EJ., van Rijn, BB., et al. Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: a systematic review. Obstet Gynecol Surv, 2011, 66, p. 225-239.
26. Kumasawa, K., et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. PNAS, 2011, 108(4), p. 1451-1455.
27. Levine, RJ., Maynard, SE., Qian, C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med, 2004, 350, p. 672-683.
28. Maynard, SE., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia. J Clin Invest, 2003, 111(5), p. 649-658.
29. Myatt, L. Placental adaptive responses and fetal programming. J Physiol, 2006, 572(Pt 1), p. 25-30.
30. Nicolaides, K. Combined screening for intermediate and late onset pre-eclampsia at 30-33 weeks of gestation. Oral communication. ISUOG: 22nd World Congress on Ultrasound in Obstetrics and Gynecology 2012/59. DGGG-Kongress 2012.
31. Norgard, B., et al. Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol, 2005, 192(3), p. 922-923.
32. Papageorghiou, AT., Yu, CK., Bindra, R., et al. Fetal Medicine Foundation Second Trimester Screening Group: Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol, 2001, 18, p. 441-449.
33. Poon, LC., Akolekar, R., Lachmann, R., et al. Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks. Ultrasound Obstet Gynecol, 2010, 35, p. 662-670.
34. Roberge, S., Giguère, Y., Villa, P., et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol, 2012, 29, p. 551-556.
35. Roberge, S., Villa, P., Nicolaides, K., et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther, 2012, 31, p. 141-146.
36. Rosser, ML., Katz, NT. Preeclampsia: an obstetrician's perspective. Adv Chronic Kidney Dis, 2013, 20(3), p. 287-296.
37. Rotchell, YE., et al. Barbados low dose aspirin study in pregnancy (BLASP): a randomized trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol, 1998, 105(3), p. 286-292.
38. Sattar, N., Greer, IA. Pregnancy complications and maternal cardiovascular risk: opportunities for intervention and screening? BMJ, 2002, 325(7356), p. 157-160.
39. Schiessl, B., et al. Prenatal constriction of the fetal ductus arteriosus-relatated to maternal pain medication? Z Geburtshilfe Neonatol, 2005, 209(2), p. 65-68.
40. Sibai, B., et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med, 1993, 329(17), p. 1213-1218.
41. Sibai, B., Dekker, G., Kupferminc, M. Pre-eclampsia, Lancet, 2005, 365, p. 785-799.
42. Sibai, BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol, 2003, 102, p. 181-192.
43. Silasi, M., et al. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am, 2010, 37(2), p. 239-253.
44. Slone, D., et al. Aspirin and congenital malformations. Lancet, 1976, 1(7974), p. 1373-1375.
45. Spencer, K., Yu, CK., Savvidou, M., et al. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol, 2006, 2, p.658-663.
46. Stepan, H., Unversucht, A., Wessel, N., et al. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension, 2007, 49, p. 818-824.
47. Stocks, G. Preeclampsia: pathophysiology, old and new strategies for management. Eur J Anaesthesiol, 2014, 31(4), p. 183-189.
48. Szostak-Wegierek, D., Szamotulska, K. Fetal development and risk of cardiovascular diseases and diabetes type 2 in adult life. Med Wieku Rozwoj, 2011, 15(3), p. 203-215.
49. Thadhani, R., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation, 2011, 124(8), p. 940-950.
50. Verlohren, S., et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol, 2012, 206, 58e1-8.
51. Wagner, SJ., et al. From placenta to podocyte: vascular and podocyte pathophysiology in preeclampsia. Clin Nephrol, 2012, 78(3), p. 241-249.
52. Werler, MM., Mitchell, AA., Shapiro, S. The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med, 1989, 321(24), p. 1639-1642.
53. Wyatt-Ashmead, J. Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol, 2011, 14(6), p. 469-474.